l 368899 has been researched along with am 630 in 1 studies
| Studies (l 368899) | Trials (l 368899) | Recent Studies (post-2010) (l 368899) | Studies (am 630) | Trials (am 630) | Recent Studies (post-2010) (am 630) |
|---|---|---|---|---|---|
| 46 | 0 | 30 | 281 | 1 | 194 |
| Protein | Taxonomy | l 368899 (IC50) | am 630 (IC50) |
|---|---|---|---|
| Cannabinoid receptor 2 | Homo sapiens (human) | 7.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kumei, S; Nozu, T; Ohhira, M; Okumura, T | 1 |
1 other study(ies) available for l 368899 and am 630
| Article | Year |
|---|---|
Central oxytocin signaling mediates the central orexin-induced visceral antinociception through the opioid system in conscious rats.
Topics: Adenosine A1 Receptor Antagonists; Analgesics; Animals; Camphanes; Cannabinoid Receptor Agonists; Dopamine D2 Receptor Antagonists; Hormone Antagonists; Indoles; Male; Naloxone; Narcotic Antagonists; Nociception; Oxytocin; Piperazines; Rats; Rats, Sprague-Dawley; Receptors, Oxytocin; Reflex; Sulpiride; Xanthines | 2019 |